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Abstract
Background: Toll-like receptors (TLRs) recognize pathogen-associated molecular patterns and their activation leads
to the induction of effector genes involving inflammatory cytokines that may have contribute to controlling
parasite growth and disease pathogenesis. The current immunogenetic study was designed to analyse the key
components of innate immunity, TLRs and TIRAP (Toll-interleukin-1 receptor domain-containing adaptor protein),
also known as MAL (MYD88 adaptor-like), in Iranian patients with mild malaria.
Methods: The tlr-4 (D299G and T399I), tlr-9 (T-1486C and T-1237C) and tirap (S180L) genes were assessed in 640
Baluchi individuals (320 Plasmodium falciparum-infected and 320 non-infected, median age of 28 years) from
malaria-endemic regions using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP)
methods.
Results: Common tlr-4 SNPs and promoter SNPs of tlr-9 were distributed among P. falciparum-infected and non-
infected groups (P > 0.05) that showed no association of these variants with mild clinical manifestation. The
comparison of the tirap S180L genotypes between patients with mild malaria and those healthy individuals
showed that the frequency of heterozygosity was significantly higher in infected than non-infected individuals
(33.8 vs. 25.6; OR, 1.479; 95% CI, 1.051-2.081; P = 0.024). The result also revealed a significant association of tirap
S180L (P < 0.05) with development of mild malaria, which is common in Baluchi populations, who are living in
malaria hypoendemic region of Iran but not in African populations (0%-6%).
Conclusion: These data point towards the need for addressing the exact role of TLRs in contributing to human
genetic factors in malaria susceptibility/resistance/severity within different malaria settings in the world.
Background
In malaria, clinical manifestations are different among
individuals who are infected with Plasmodium falci-
parum, ranging from asymptomatic infection to severe
life-threatening forms. The development of severe
malaria is due to the marked changes in cytokine
expression that results in the individual’s immune
response to parasites. Indeed, the pathogenesis of severe
malaria is complex and so far, the sequence of events
leading to severe malaria is not completely known. To
understand why some infections lead to severe forms of
the disease, research has been focused on identifying
parasite virulence phenotypes and the genetic make-up
of the host [1].
Toll-like receptors (TLRs) have been defined as pattern-
recognition receptors whose function is to recognize
pathogen-associated molecular patterns (PAMPs), includ-
ing microbial pathogens, virulence factors and intracellular
protozoan parasites [2-4]. The activation of TLRs leads to
the induction of effector genes involving inflammatory
cytokines and, as a result, provides links between innate
and adaptive immunity [5]. In vitro and in vivo results
showed that TLRs (TLR-2, TLR-4, and TLR-9) are central
mediators of pro-inflammatory responses to Plasmodium
infection [6-12]. The adaptor protein TIRAP (Toll-
interleukin-1 receptor domain-containing adaptor pro-
tein), also known as MAL (MYD88 adaptor-like), mediates
downstream signaling of TLR-2 and TLR-4 inducing
pro-inflammatory responses [13].
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described for tlr-4, tlr-9 and tirap genes that alter sus-
ceptibility to infectious and inflammatory diseases [14].
For tlr-4, the most extensively studied genetic variations
are two frequently non-synonymous co-segregating
SNPs (D299G/T399I) that change the ligand-binding
site of the receptor [15]. tlr-4 polymorphisms are
assumed to be correlated with risk of severe malaria as
reported by Mockenhaupt and colleagues [7]. Two com-
mon tlr-9 promoter SNPs, T-1486C (rs1870884) and T-
1237C (rs5743836) are assumed to be associated with
susceptibility to asthma [16] and placental malaria [8],
respectively. The adaptor protein tirap S180L SNP
(rs8177374) has been reported to diminish TLR-2 and
TLR-4 signaling [3,13] and heterozygosis for this SNP
has been claimed to confer protection against mild and
severe malaria to an extent comparable to HbAs [17].
Regarding the association between human gene poly-
morphism and disease, most studies for malaria suscept-
ibility/resistance have been conducted on populations
from Africa and south-east Asia. There is no informa-
tion on malaria-associated gene polymorphisms from
Iran, where malaria transmission is hypoendemic and
there is no record of severe malaria and death due to
this disease is rare. Up to this time, it is difficult to con-
firm the association between certain TLR polymorph-
isms and malaria susceptibility due to differences in
ethnicity, location, environmental factors and exposure
to infectious pathogen; hence, conducting different stu-
dies on various populations are needed to clarify this
issue. Therefore, the current study was designed to look
at the polymorphisms in tlr-4 and tlr-9 genes in Baluchi
ethnic groups from south-eastern parts of Iran with
unstable and hypoendemic malaria transmission. In
addition, SNP in tirap, which is a common adaptor pro-
tein for TLR-2 and TLR-4, was assessed. Finally, the fre-
quencies of the common SNPs, observed in tlr-4, tlr-9
and tirap genes, among Baluchi patients with mild
malaria and healthy control individuals were compared.
The obtained results might enable us to understand the
nature and outcome of the malaria disease in humans,
and evaluate novel diagnostic and therapeutic strategies
for this disease.
Methods
Study areas and population
Malaria is endemic in Sistan and Baluchistan Province
(Iran), and the transmission is year-round with two
peaks, the first from May to August with Plasmodium
vivax as the predominant species and the second from
October to November when both P. falciparum and
P. vivax infections are usually recorded. In 2008,
approximately 11,460 malaria cases were reported in
Iran, 10% of which were microscopically diagnosed as
P. falciparum. Most of the cases (94%) were recorded in
the south-eastern provinces and in these regions; there
is no report of severe malaria, anaemia or death due to
malaria. Moreover, most patients were adults with
uncomplicated malaria.
The study population was consisted of 640 Baluchi
individuals (420 men and 220 women; median age of
28 years) from malaria endemic region of Sistan and
Baluchistan Province. The patients (n = 320) with febrile
P. falciparum were recruited in an outpatient clinic at
primary health centers in Chabahar district during April
2004-November 2009. These patients, who were pre-
sented with malaise, fever, or muscular pain and head-
ache, were considered symptomatic and classified as
having mild malaria (210 men and 110 women, median
age of 28 years) and parasitaemia was ranged 1,000 to
35,000 asexual parasites/mm
3. All patients who were
infected with P. falciparum had a fever and the diagnosis
was confirmed via microscopy. Healthy Baluchi indivi-
duals (n = 320, 205 men and 115 women; median age of
27 years) with no history of febrile or malaria clinical
symptoms were included as control. Nested PCR was
used to confirm infection and also co-infection with
P. vivax in both patient and control groups. After obtain-
ing an informed consent from adults or the parents or
legal guardians of children, 1 ml of blood was collected
from the individuals in vacuum EDTA tubes and stored
at -20°C. All individuals with fever and confirmed malaria
were treated according to the national guidelines. This
study was approved by the Ethical Review Committee of
Research in Pasteur Institute of Iran.
Detection of parasites by nested-PCR assay
Genomic DNA was isolated from whole blood collected
in EDTA tubes, by using the commercially available
DNA purification kit (Promega, Madison, WI, USA),
and kept at -20°C until use. DNA of Plasmodium
species (P. vivax and P. falciparum) was detected by
nested-PCR amplification of the small sub-unit riboso-
mal ribonucleic acid (18ssrRNA) genes using the pri-
mers and cycling parameters described previously [18].
The amplified products were resolved by 2%-2.5%
agarose gel electrophoresis and stained with ethidium
bromide for visual detection by ultraviolet trans-
illumination.
Genotyping and SNPs detection by PCR-RFLP
The non-synonymous SNPs of tlr-4 D299G and T399I,
the two promoter SNPs of tlr-9 at positions T-1486C
and T-1237C as well as tirap S180L SNPs were studied.
The different SNPs were identified by PCR-RFLP analy-
sis. The primers, PCR cycling conditions and RFLP are
shown in Table 1. All amplifications were carried out in
af i n a lv o l u m eo f2 5μL including 1 μLo ft e m p l a t e
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centration of 250 nM and the reaction mixture con-
tained 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 2 mM
MgCl2, each of the four deoxynucleotide triphosphates
at a concentration of 125 μM, and 0.2 U of Taq poly-
merase (Invitrogen, Carlsbad, CA). The DNA fragments,
obtained following PCR amplification or RFLP analysis,
were electrophoresed on 2% to 3% agarose gels (Invitro-
gen, Carlsbad, CA), respectively.
DNA sequence analysis
To verify the results obtained by RFLP, all PCR products
were sequenced for tlr-4, tlr-9 and tirap genes using the
primers described in Table 1. Therefore, the amplified
fragments were gel-purified using the QIAquick Gel
Extraction kit (Qiagen, Hilden, Germany) following the
manufacturer’s instructions. Direct sequencing of the
DNA fragments was performed in both directions for
each PCR product using the dideoxy chain termination
procedure (Chemistry V3.1, Applied Biosystems) and
also the 3730XL DNA analyser (Applied Biosystems) by
MilleGen sequencing service (Labege, France).
Statistical analysis
T h es a m p l es i z ew a sc a l c u l a t e du s i n gO p e n E p is o f t w a r e
[19], with 80% power and 95% confidence level. Allele
and genotype frequencies were calculated for different
genes by direct counting. The comparison of the allele
and genotype frequencies of the study groups was deter-
mined by X
2 test using SPSS for windows (version 16.0)
and P < 0.05 was considered to be significant. To deter-
mine if genetic variation in tlr-4, tlr-9 and tirap genes
were associated with risk of developing malaria, odds
ratios (OR) and 95% confidence intervals (CIs) were cal-
culated. The Hardy-Weinberg Equilibrium (HWE) was
performed by comparing the observed numbers of dif-
ferent genotypes with those expected under the HWE
for the estimated genotype frequencies [20] and P >
0.05 was in HWE. Genotypic deviations from HWE
were assessed using Pearson’sc h i - s q u a r e( X
2) statistical
test.
Results
Based on nested-PCR results, a total of 320 patients
with mild malaria were shown to be infected with
P. falciparum, as a mono-infection, and none of the
healthy control individuals had either P. falciparum or
P. vivax infections.
tlr-4, tlr-9 and tirap polymorphisms
Overall, P. falciparum-infected (n = 320) and non-
infected (n = 320) Baluchi individuals were successfully
analysed for the tlr-4, tlr-9 and tirap SNPs by PCR-
RFLP methods and the sequencing data confirmed RFLP
results. To determine whether there was any frequency
difference in the allele (Table 2) and genotype (Table 3)
Table 1 Primers and profiles used for PCR-RFLP of the tlr-4, tlr-9 and tirap genes
Temperature °C/
time (min)
Genes Primer Sequence A E D C Product
size (bp)
Restriction Enzyme Cut Product Size (bp)
299TLR4F ATACTTAGACTACTACCTCCATG 56
(1)
72
(1)
94
(1)
35 213 NcoI (Fermentase) G: 19 + 194
tlr-4* 299TLR4R TTGTTGGAAGTGAAAGTAAG
399TLR4F TGTTATCAAAGTGATTTTGGGAGAA 54
(1)
65
(1)
94
(1)
35 185 Hinf I (Fermentase) I: 162 + 23
399TLR4R AGGTAAATGAGGTTTCTGAGTGATAGG
-1237TLR9F TTCATTCAGCCTTCACTCAG T: 264+145+126+23
tlr-9 -1237TLR9R TCAAAGCCACAGTCCACAG 64
(1)
72
(1)
94
(1)
30 558 BslI (Fermentase) C: 264+115+126+ 30+23
-1486TLR9F TTCATTCAGCCTTCACTCAG 64
(1)
72
(1)
94
(1)
30 558 AflII (Fermentase) T: 413 + 145
-1486TLR9R TCAAAGCCACAGTCCACAG
180 TIRAP F AGTGCTGTACCATCGACCTGCTG
tirap ** 180 TIRAP R TTCCCCTTCTCCCTCCTGTAGTAG 60
(1)
72
(1)
94
(1)
35 161 Eam1105I (Fermentase) S: 141 + 20
All primers described in this study were designed in our laboratory (GenBank accession no. AF177765.1 for tlr-4; NW-001838877.2 for tlr-9 and NT-033899.7 for
tirap) except 299TLR4F primer that was described previously [26]. The bold and underline nucleotides located in the 3’ of forward primers indicate a mutation,
and create a restriction site accordingly.
A: Annealing, E: Extension, D: Denaturation, C: No. of cycles.
* tlr-4 (gat) D299G (ggt).
* tlr-4 (acc) T399I (atc).
** tirap (tcg) S180L (ttg).
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between the two studied groups. All examined SNPs
were presented in studied populations at different fre-
quencies. The frequencies for two polymorphic alleles in
tlr-4 (D299G and T399I) and tlr-9 (T-1237C) were less
than 10% and those for polymorphic alleles in tlr-9
(T-1486C) and tirap (S180L) were greater than 10%
(Table 2) in infected patients. Furthermore, there were
no significant differences in all examined SNPs frequen-
cies among Baluchi patients with mild malaria and
related case controls (P > 0.05, Table 2).
Frequencies of tlr-4, tlr-9 and tirap genotypes
The three genotypes of tlr-4 D299G were present in
Baluchi infected individuals, but tlr-4 G299G
Table 2 Allele frequencies for the tlr-4, tlr-9 and tirap
polymorphisms in P. falciparum-infected and non-
infected subjects
Allele frequency
Gene
(Polymorphism)
Non-infected Infected P value
WMW M
tlr-4 D299G 0.948 0.052 0.923 0.077 0.068
T399I 0.921 0.079 0.923 0.077 0.835
tlr-9 -1486 0.651 0.349 0.646 0.354 0.815
-1237 0.898 0.102 0.923 0.077 0.116
tirap S180L 0.862 0.138 0.825 0.175 0.065
W = wild allele.
M = mutant allele.
Table 3 Genotype frequencies for the tlr-4, tlr-9 and tirap polymorphisms in P. falciparum-infected and non-infected
subjects
Genotype Frequency
Gene
(Polymorphism)
Observed expected P
(HWE, X
2)
OR
(95% CI)
P
value
Genotype Non-infected No
(%)
Infected No
(%)
Non-infected No
(%)
Infected No
(%)
W (D/D) 287 (89.7) 276 (86.3) 288 (90) 273 (85.3) 0.721
(0.446-1.166)
0.181
D299G H (D/G) 33 (10.3) 39 (12.1) 31 (9.7) 45 (14.1) NI = 0.33
I = 0.013
1.161
(0.709-1.899)
0.553
tlr-4 M (GG) - 5 (1.6) 1 (0.3) 2 (0.6) - -
W (T/T) 270 (84.4) 271 (84.7) 272 (85) 273 (85.3) 1.024
(0.667-1.572)
0.913
T399I H (T/I) 50 (15.6) 49 (15.3) 46 (14.4) 45 (14.1) NI = 0.125
I = 0.138
0.976
(0.636-1.499)
0.913
M (I/I) - - 2 (0.6) 2 (0.6) - -
W (TT) 130 (40.6) 142 (44.4) 136 (42.5) 133 (41.6) 1.166
(0.852-1.596)
0.337
T-1486C H (TC) 157 (49.1) 130 (40.6) 145 (45.3) 147 (45.9) NI = 0.149
I = 0.058
0.710
(0.520-0.971)
0.032
tlr-9 M (CC) 33 (10.3) 48 (15) 39 (12.2) 40 (12.5) 1.535
(0.956-2.464)
0.075
W (TT) 270 (84.4) 276 (86.2) 258 (80.6) 273 (85.3) 1.162
(0.749-1.801)
0.503
T-1237C H (TC) 35 (10.9) 39 (12.2) 59 (18.4) 45 (14.1) NI < 0.0001
I = 0.0135
1.130
(0.696-1.836)
0.621
M (CC) 15 (4.7) 5 (1.6) 3 (1) 2 (0.6) 0.323
(0.116-0.899)
0.023
W (S/S) 235 (73.4) 210 (65.6) 238 (74.4) 218 (68.1) 0.691
(0.492-0.969)
0.032
tirap S180L H (S/L) 82 (25.6) 108 (33.8) 76 (23.7) 92 (28.8) NI = 0.150
I = 0.0025
1.479
(1.051-2.081)
0.024
M (L/L) 3 (1) 2 (0.6) 6 (1.9) 10 (3.1) 0.665 (0.11-4.004) 0.653
NI: non-infected.
I: P. falciparum-infected.
HWE: Hardy-Weinberg Equilibrium (P < 0.05).
W: Wild type allele, H: Heterozygote allele, M: Mutant type allele.
OR: Odds ratios.
CI: Confidence interval.
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(Table 3) that might suggest an association of this
genotype with mild malaria clinical symptoms (1.6%,
P = 0.025). In addition, two genotypes of tlr-4 T399T
and tlr-4 T399I were observed among cases and con-
trols with no significant difference (P > 0.05). tlr-4 I399I
homozygous was absent in both studied groups (Table
3). The comparison of the tlr-9 T-1237C and T-1486C
genotypes between patients with mild malaria and those
healthy individuals showed that the three tlr-9 T-1237C
and T-1486C genotypes were present among both stu-
died groups (Table 3). Heterozygosity for tlr-9 T-1486C
was more prevalent among case controls (49.1%) than
among malaria patients (40.6%, Table 3). tlr-9 C-1486C
homozygote was also found in both P. falciparum-
infected (15%) and non-infected cases (10.3%) with no
statistically significant (P > 0.05). Furthermore, tlr-9
T-1237C frequency was low in the cases (1.6%) and con-
trols (4.7%). The comparison of the tirap S180L geno-
types between patients with mild malaria and those
healthy individuals showed that the frequency of hetero-
zygosity was significantly higher in infected than non-
infected individuals (33.8 vs. 25.6; OR, 1.479; 95% CI,
1.051-2.081; P = 0.024) (Table 3).
Discussion
Severe malaria accounts for many of deaths due to the
infection with P. falciparum. Areas of intense malaria
transmission such as African countries tend to have a
greater proportion of severe cases, whereas the oppo-
site is seen in areas of lower transmission [21]. Addi-
tionally, in some other malaria endemic regions of the
world, including Iran, the severe cases are very rare.
This, in turn, raises the question of why small subset
of P. falciparum-infected individuals develops the
severe and complicated disease but, others develop a
mild and uncomplicated disease or remain asympto-
matic. To verify and provide further data on this issue,
different studies showed the contribution of host
genetic factors to the severe outcome following infec-
tion [22] and since then, several genes have been
shown to be involved in protection or susceptibility to
severe malaria including TLRs that play an important
role in innate immunity [23].
Mockenhaupt and co-workers [7] investigated tlr-2,
tlr-4 and tlr-9 polymorphisms in African children. They
found that a common tlr-4 D299G increases the risk of
severe paediatric malaria without affecting on the risk of
infection. However, in the present study, 10% of the par-
ticipants in both groups had less than 15 years old with
no sign of severe disease. In addition, in both studied
groups, the frequency of tlr-4 D299G was low and simi-
lar. Therefore, this result suggested that more studies on
different populations from malaria endemic regions with
various endemicity are needed to draw final conclusion
on the role of tlr-4 D299G and its association with
malaria manifestation. On the other hand, study by
Mockenhaupt and colleagues [7] showed that tlr-4
T399I predisposes to severe malaria with symptoms
such as severe anaemia and respiratory distress. This
suggests that tlr-4 might be involved in P. falciparum
recognition and host responses in humans, and that
tlr-4 could contribute to the control of the infection.
However, in this study, tlr-4 T399I genotype has been
observed in malaria patients and healthy individuals
with no statistically significant that showed no associa-
tion of this genotype with mild clinical manifestation.
In the next step, the frequency of promoter poly-
morphisms of tlr-9 was assessed in target population.
tlr-9 T-1486C heterozygote and homozygote were found
in both P. falciparum-infected and non-infected cases,
with no association with mild malaria, which was in line
with other findings [7,24]. Furthermore, tlr-9 T-1237C
frequency was low in the cases and controls with no
association with mild malaria. To date, the functional
roles of this promoter SNP and of T-1486C are unclear,
but our data argues against a major role of these poly-
morphisms in malaria manifestations.
Study by Khor and colleagues [17] in Gambia, Kenya
and Vietnam revealed that tirap S180L heterozygosity
was associated with a significant protective effect against
both mild and severe malaria. In addition, study by
Leoratti and co-workers [24] in Brazilian populations
showed that no association of this genotype was found
with mild malaria. In contrast, in the present study,
there was a high frequency of heterozygosity (tirap
S180L) in Baluchi infected individuals than controls
(33.8% vs. 25.6%). The comparison of healthy and
infected individuals showed that the risk of mild malaria
was increased 1.5-fold in individuals with tirap S180L
(OR, 1.479; 95% CI, 1.051-2.081, P = 0.024). It is worth
mentioning that the frequency of this heterozygosity
was higher among Iranian infected patients with
P. falciparum (33.8%), who are living in malaria hypoen-
demic areas (present study), than Ghanan, Gambian,
Kenyan and Vietnamese populations (0%-3.5%) with
reported severe cases of malaria [25,17]. In fact, the pre-
sence of the high frequency of tirap S180L variant in
Iranian malaria patients with mild malaria might sup-
port the role of this SNP in protection against severe
malaria by intermediate levels of pathway activation and
balanced inflammatory response (by attenuates TLR-2
and TLR-4 signaling pathways).
Moreover, homozygous tirap L180L was found in both
infected and non-infected Baluchi individuals (0.6% vs.
1%), which was not reported in African and Vietnamese
populations, where malaria is highly endemic. The rarity
of the mutant allele in African populations might be
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to malaria, thus this may strongly reduce the frequency
of tirap L180L genotype in these regions. This homozy-
gousity suggested to be a risk factor for several diseases,
including malaria [25], which is in contrast with the pre-
sent finding (OR, 0.665; 95% CI, 0.11-4.004; P = 0.653).
The specific role of tirap L180L on malaria disease pro-
cesses needs further investigation in different ethnic
groups.
Overall, wild-type homozygosity for all three examined
genes was predominant among patients with mild
malaria and healthy control groups. Statistical analysis
also showed that all of SNPs were in HWE in the con-
trol group except for tlr-9T - 1 2 3 7 C .I na d d i t i o n ,t h e
observed genotype frequencies in the patients with mild
malaria were significantly different from the expected
frequencies for tlr-4 D299G, tlr-9 T-1237C and tirap
S180L SNPs, which are deviated from HWE. This could
be explained by genetic drift, non-random mating or an
indication of selection acting on specific genotype and
at the present, there is no any evidence to prove any of
them in this population.
Conclusion
In summary, in the current immunogenetic study, it
seems that the role of TLR polymorphisms is varying in
different ethnic groups from different malaria endemi-
city. High frequency of heterozygous tirap S180L in
malaria infected individuals point to the role of this gen-
otype as a risk factor for the development of mild
malaria, but protect from severe malaria. Comparing
these data with previously reported results from other
malaria endemic regions [17,25] suggests a need for
addressing the exact role of TLRs and TIRAP in
contributing to human genetic factors in malaria sus-
ceptibility/resistance/severity within different malaria
transmission settings and manifestation pattern in the
world.
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